Ingrid Torjesen
Hard-to-treat psoriasis cases respond to secukinumab
Secukinumab has been shown to be effective for the treatment of moderate-to-severe plaque psoriasis in hard-to-treat patients who failed anti-TNFa treatment, researchers report in London.
Promising results for risankizumab continue in phase 3 trials
Phase three trials of the selective IL-23 blocker risankizumab are replicating the promising results achieved by phase two trials for psoriasis, researchers report in London.
Restarting TNFi treatment after a break proves beneficial in psoriasis
Switching from adalimumab to etanercept or vice versa after interruption can improve treatment response, data presented in London suggests.
Psoriasis patients have a heightened risk of malignant lymphoma
Patients with psoriasis are more likely than the general population to receive a diagnosis of malignant lymphoma. Why? Cutaneous T-cell lymphoma is misdiagnosed as psoriasis and can also be mistaken for atopic dermatitis due to similarities in the skin manifestation.
Caffeine can reduce inflammation in patients with eczema and psoriasis
Adding caffeine to topical skin treatments would be a simple way to reduce inflammation in patients with atopic dermatitis and psoriasis, suggests a review presented at the Psoriasis: From Gene to Clinic International Congress, which took place in London this week.
  • 1
  • 2

Poll

View Results